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Abstract:
Purinergic signalling is important both in short-term control of vascular tone and in longer-term control of cell proliferation,
migration and death involved in vascular remodelling. There is dual control of vascular tone by ATP released from perivascular
nerves and by ATPreleased from endothelial cells in response to changes in blood flow (shear stress) and hypoxia. Both ATPand its
breakdown product, adenosine, regulate smooth muscle and endothelial cell proliferation. The involvement of these regulatory
mechanisms in pathological conditions, including hypertension, atherosclerosis, restenosis, diabetes and vascular pain, are
discussed.
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Introduction
The concept of purinergic signalling, i.e. ATP acting
as an extracellular signalling molecule, was proposed
by Burnstock in 1972 when evidence was presented
that ATP was the neurotransmitter in non-adrenergic,
non-cholinergic neuromuscular transmission in the
gut and urinary bladder [21]. Later, it was recognised
as a cotransmitter in sympathetic, parasympathetic,
sensory-motor and enteric nerves [10]. There was early
resistance to this concept (see [12, 22, 26]), but the roles
of nucleotides and nucleosides as extracellular signal-
ling molecules are now well established in both neural
and non-neural tissues [2, 18, 27]. P1 receptors for
adenosine, of which four subtypes (A￿,A ￿￿,A ￿￿, and
A￿) have been cloned and characterised, have been
distinguished from P2 receptors for ATP/ADP/UTP
[8], and P2 receptors have been divided into P2X
ligand-gated ion channel and P2Y G protein-coupled
receptor families. Seven subtypes of P2X receptors
and 8 subtypes of P2Yreceptors have been cloned and
characterized [19, 79]. The majority of studies involv-
ing purinergic signalling have been concerned with
short-term events, such as neurotransmission or secre-
tion. However, there is growing interest in the long-
term trophic actions of extracellular nucleotides and
nucleosides on cell proliferation and death [1, 75].
ATP and adenosine are very much involved in the
mechanisms underlying local control of vessel tone
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In the vascular system, short-term purinergic signal-
ling events associated with the control of vascular
tone by ATP released from nerves and endothelial
cells have been clearly demonstrated [11, 24, 28] (see
Fig. 1).
ATP released as a cotransmitter with noradrenaline
(NA) from perivascular sympathetic nerves acts
mainly on P2X￿ receptors on medial vascular smooth
muscle to produce constriction, whereas ATP released
as a cotransmitter from sensory-motor nerves during
‘axon reflex’activity dilates some vessels [28].
ATP released from endothelial cells during changes
in blood flow (producing shear stress) or hypoxia acts
on P2 receptors on endothelial cells to release nitric
oxide (NO), resulting in relaxation [4, 24]. P2Y￿ re-
ceptors are dominant in some vessels activated selec-
tively by ADP [79], in other vessels P2Y￿ receptors
are present that are activated equally by ATP and the
pyrimidine UTP [72]. UTP has also been shown to be
released from endothelial cells by shear stress [85].
Endothelial cells also express other types of puriner-
gic receptors (P2Y￿ and P2Y￿) [78]; and yet another
P2Y receptor subtype (P2Y￿￿) is present on endothe-
lial cells of human mammary artery and umbilical
vein [104]. Endothelial cells of arteries and veins ex-
press different levels of P2X￿ receptors – high levels
on saphenous veins and low levels on mammary arter-
ies, although the function of this receptor was un-
known [81]. However, Yamamoto et al. [107] re-
ported that, in some blood vessels, P2X￿ receptors in-
duced vascular dilatation in an NO-dependent
manner. This finding contrasts with another study that
examined P2X￿ receptors on the endothelium of rat
mesenteric arteries. P2X￿ receptors mediated endoth-
elial-dependent vasodilation, but a NO synthase in-
hibitor had no effect on dilation [50]. P2X￿ and P2X￿
receptors (perhaps as heteromultimers) were reported
to be associated with VE-cadherin in human endothe-
lial cells, suggesting a role for these receptors in
modulating adhesion junctions between endothelial
cells [46].
Adenosine produced after breakdown of released
ATP from nerves and endothelial cells causes vaso-
dilatation via smooth muscle P1 (usually A￿ subtype)
receptors. ATP release from red blood cells is in-
creased in pathological conditions such as subarach-
noid hemorrhage, largely because there is widespread
blood cell lysis [92]. This leads to transient constric-
tion of arterioles via P2X receptors and sustained con-
striction of large cerebral vessels, largely through
P2Y￿ receptors. The differences in purinergic receptor
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cerebral circulation are likely to have important con-
sequences in pathological conditions.
Long-term purinergic signalling involved
in proliferation of smooth muscle and
endothelial cells
Smooth muscle
An early study reported that adenosine produces
changes in cyclic AMPand DNAsynthesis in cultured
arterial smooth muscle cells and suggested that this
might result in the regulation of cell proliferation
[57]. The authors speculated that adenosine could be
one of several regulatory factors in the development
of atherosclerosis and might also regulate the release
of a smooth muscle mitogen, platelet-derived growth
factor (PDGF), from platelets. There is now good evi-
dence that adenosine, an ectoenzymatic breakdown
product of ATP, does regulate smooth muscle cell pro-
liferation, but its properties differ from those for ATP
and ADP. Adenosine inhibits vascular smooth muscle
cell proliferation by A￿￿ receptor activation via the
elevation of cyclic AMP [37] and a selective A￿ re-
ceptor agonist, 2-octynyladenosine, reduced neointi-
mal thickening in a rat femoral artery injury model
[95].
ATP and ADP stimulate DNA synthesis and cell
proliferation of cultured porcine artery vascular
smooth muscle cells, an action that was shown to be
mediated by P2Y receptors [103]. It was speculated
that this mechanism was involved in the regulation of
vascular smooth muscle cell proliferation during em-
bryonic and early postnatal development, after injury,
and in arteriosclerosis. It was further suggested that
the ATP released from endothelial cells causes not
only autocrine mitogenic stimulation of the endothe-
lial cells themselves but also paracrine stimulation of
the smooth muscle cells that migrate to the intima af-
ter injury. Exogenous ATPand UTPalso induce a lim-
ited cell cycle progression in arterial smooth muscle
cells as well as having powerful mitogenic actions,
probably via P2Y￿ or P2Y￿ receptors [41, 68, 71].
Sympathetic nerves have been shown to exert a tro-
phic influence on vascular smooth muscle [3, 90].
From her studies of pulmonary artery denervated of
sympathetic nerves, Bevan [3] concluded that sympa-
thetic transmitters exert slow trophic as well as fast
signalling actions on cell growth and division by in-
fluencing protein, DNA, and RNA synthesis. Since
ATP as well as NA and neuropeptide Y (NPY) are
known to be released as cotransmitters from sympa-
thetic nerves [15], this was consistent with the possi-
bility that ATP and/or its breakdown product, adeno-
sine, might be involved in these trophic actions.
ADP contributes significantly in synergy with the
peptide growth factors PDGF, epidermal growth fac-
tor, and transforming growth factor-, to the platelet-
induced proliferation of vascular smooth muscle [33].
The mitogenic effect of ATP on vascular smooth mus-
cle cells is synergistic with other mitogens, including
insulin and insulin-like growth factor-1 [103]. In
a study of the mechanisms involved in ATP-induced
proliferation of vascular smooth muscle cells [108], it
was shown that P2Y receptor activation of smooth
muscle was coupled to a pertussis toxin-insensitive
G￿ protein, triggering phosphoinositide hydrolysis
and subsequent activation of PKC, Raf 1 and MAPK.
A later study presented evidence indicating that ATP-
stimulated vascular smooth muscle cell proliferation
requires independent ERK and phosphatidylinositol
3-kinase–signalling pathways [105]. There are 2 phe-
notypes of smooth muscle: the contractile phenotype
and the synthetic (proliferative) phenotype [30]. In
a study of cultures expressing these 2 phenotypes us-
ing quantitative reverse transcription-polymerase
chain reaction, it was shown that P2X￿ receptors were
strongly expressed in the contractile phenotype. In the
synthetic (proliferative) phenotype, the mitogenic
P2Y￿ and P2Y￿ receptor transcripts were upregulated
342- and 8-fold, respectively, whereas the contractile
P2X￿ receptor was totally down-regulated, while the
P2Y￿ and P2Y￿ receptors were unchanged [40]. Fur-
thermore, MAPK kinase-dependent growth factor in-
duced the upregulation of P2Y￿ receptors in vascular
smooth muscle cells, which the authors suggested
may be of importance in atherosclerosis and neointi-
mal formation after balloon angioplasty [53].
Endothelial cells
Long-term administration of adenosine was reported
to induce capillary endothelial cell proliferation in the
heart [54]. Adenosine has also been shown to induce
dose-dependent proliferation of endothelial cells ob-
tained from the aorta [98], from coronary vessels
14 ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿ ￿ ￿￿￿￿￿ ￿￿￿ ￿￿￿￿￿[111] and from human umbilical veins [42]. It has also
been shown to stimulate canine retinal microvascular
endothelial cell migration and tube formation [67].
The action of adenosine in producing endothelial cell
proliferation is mediated by A￿￿ and A￿￿ receptors
partly by the modulation of vascular endothelial
growth factor (VEGF) [48, 88]. The addition of an an-
tisense oligonucleotide complementary to the A￿￿ re-
ceptor mRNA inhibited VEGF production. Augmen-
tation by adenosine of the expression of VEGF has
been described in cerebral [43] and retinal [94] micro-
vascular endothelial cells. The selective A￿￿ receptor
antagonists enprofylline and 3-isobutyl-8-pyrro-
lidinoxanthine inhibited 5’-(N-ethylcarboxamido)-
adenosine-stimulated proliferation of human retinal
endothelial cells, ERK activation, cell migration, and
capillary tube formation [47].
ADP was shown to be one of several agonists that
induced cultured endothelial cell migration and prolif-
eration [70]. Angiogenesis (or neovascularization) be-
gins with the migration of endothelial cells, originat-
ing from capillaries, into the tissue being vascular-
ized. ADP and, to a lesser extent, adenosine and
adenine showed strong chemotactic activity and were
postulated to be angiogenesis factors in vivo [96].
Adenine nucleotides were shown to have a mitogenic
action on aortic endothelial cells, probably via P2Y
receptors [97]. ATP has also been shown to produce
proliferation of cultured bovine corneal endothelial
cells [31]. The source of the purines involved in these
trophic actions is largely from the endothelial cells,
suggesting an autocrine mechanism [66]. ADP re-
leased from aggregating platelets may also play a role
[99]. Stretch-induced changes in endothelial cell
shape [106] and changes produced by hypoxic stress
may be mediated by the ATP (and adenosine after ec-
toenzymatic breakdown) released from endothelial
cells under both these conditions (see [5]).
There is increasing evidence that cell proliferation
and programmed cell death (apoptosis) are linked
[35]. For example, VEGF turns on cell proliferation,
but inhibits apoptosis [69]. Distinct signal transduc-
tion cascades, composed of at least 3 protein kinases,
mediate cell proliferation and differentiation, growth
arrest, and apoptosis [73]. In diseases such as carcino-
genesis, degenerative disorders, and ischemia/reper-
fusion injury, there is an imbalance between cell divi-
sion and cell death. Extracellular ATP and adenosine
have been shown to cause apoptosis of pulmonary ar-
tery endothelial cells [34]. It has been speculated that
ATP released from cells undergoing cytolysis or de-
granulation may cause endothelial cell death, perhaps
by inhibition of methyltransferase activity and that
this may be important in acute vascular injury or in
limiting angiogenesis [84]. ATP converts necrosis to
apoptosis in oxidant-injured bovine pulmonary artery
endothelial cells [65]. In a study of porcine aortic en-
dothelial cells, extracellular ATP and ADP, probably
acting through P2X￿ receptors, were shown to acti-
vate nuclear factor-B, a transcription factor, and in-
duce apoptosis [102].
Purinergic signalling in vascular
diseases
The migration, proliferation, and death of vascular
smooth muscle and endothelial cells play an impor-
tant role in the development of intimal thickening dur-
ing arterial diseases, such as arteriosclerosis and res-
tenosis after angioplasty, and in the growth of new
vessels that takes place during wound healing and in
tumors [45, 83, 87]. ATP, ADP, UTP, and adenosine
play pivotal signalling roles in these long-term events
[23, 38, 39, 74, 80].
Hypertension
ATP plays a significant cotransmitter role in sympa-
thetic nerves supplying hypertensive blood vessels.
The purinergic component is increased in spontane-
ously hypertensive rats (SHR) [6, 101]. The increase
in sympathetic nerve activity in hypertension is well
established, and there is an associated hyperplasia and
hypertrophy of arterial walls [58]. Also, sympathetic
neurons innervating the vasculature are dependent on
nerve growth factor (NGF) in development, and an in-
crease in NGF gene expression and protein has been
described in spontaneously hypertensive rats (SHR)
[109]. ,-Methylene ATP has been shown to in-
crease NGF secretion by vascular smooth muscle
cells in SHR [91]. ATP is a rapidly acting hypotensive
agent that compares favourably with sodium nitro-
prusside [63]. ATP-MgCl￿ is a safe, effective, and
preferential pulmonary vasodilator in children with
pulmonary hypertension secondary to congenital
heart defects; it has also been used for treating pulmo-
nary hypertension after cardiac surgery [7]. ATP ex-
￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿ ￿ ￿￿￿￿￿ ￿￿￿ ￿￿￿￿￿ 15
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￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿erts mitogenic actions on human pulmonary artery
smooth muscle cells, which may be relevant to the pa-
thophysiological basis of severe pulmonary hyperten-
sion [59, 110]. Eicosapentaenoic acid, one of the ac-
tive components in fish oil that has antihypertensive
effects, increases the release of ATP from vascular en-
dothelial cells, leading to reduction of the blood pres-
sure rise characteristic of aging [51]. P2X￿ receptors
are localized in the syncytiotrophoblast, stroma, and
foetal capillary endothelial cells of human placenta.
Placental P2X￿ receptors are significantly upregulated
in mild preeclampsia [82].
Angiogenesis
The growth of new blood vessels takes place in patho-
logical events such as tumor growth, wound healing,
psoriasis, and the ischemic retinopathies that occur in
diabetes and sickle cell disease. In the adult, the de-
velopment of new blood vessels, or neovasculariza-
tion, occurs by budding from existing blood vessels
and is referred to as angiogenesis (as distinct from
vasculogenesis, which occurs in embryogenic devel-
opment by vessel formation from mesenchyme pre-
cursor cells or angioblasts). Peptide growth factors
such as fibroblast growth factor, transforming growth
factor-, and VEGF are clearly involved in angio-
genesis, but purines and pyrimidines also contribute
to this process [86]. In rheumatoid arthritis, new cap-
illary blood vessels invade the joint and destroy the
cartilage. In diabetes, new capillaries in the retina in-
vade the vitreous body, bleed, and cause blindness,
and tumor growth and metastasis are angiogenesis de-
pendent [44]. Anginal patients treated chronically
with dipyridamole to increase adenosine levels
showed an increase in coronary angiogenesis [76],
and dipyridamole has also been used for the preven-
tion of stroke [36]. The former action may involve
a preferential effect of adenosine on endothelial cells,
since smooth muscle proliferation was inhibited in
rabbits pre-treated with dipyridamole [55].
Atherosclerosis
Vascular injury represents a critical initiating event in
the pathogenesis of various vascular diseases, includ-
ing organ transplantation, sepsis, and atherosclerosis,
and the events that follow, i.e., vascular cell growth,
migration, proliferation, and death. Since large
amounts of ATP are released from injured cells and
because ATP and its breakdown product, adenosine,
have potent actions in smooth muscle and endothelial
cell growth, migration, proliferation, and death, the
possibility that purines are one of the factors involved
in the development of vascular disease has been con-
sidered. Various models of vascular injury have been
introduced, including denudation of the endothelium
by mechanical injury (balloon or nylon catheters),
diet-induced hypercholesterolemic injury, or immune
injury. A limited number of studies have been carried
out to examine the possible roles of purines in the de-
velopment of the pathology of vessels.
Atherosclerotic damage results in the disappear-
ance of endothelium-dependent vasodilator responses
to ATP [77, 100], whereas the relaxing action of
smooth muscle is unimpaired. The release of ATP
from endothelial cells has been claimed to be im-
paired in atherosclerotic rat caudal arteries [89].
Long-term supplementation with a high cholesterol
diet decreases the release of ATP from the caudal ar-
tery of aged rats [52]. Changes in the dual nervous
and endothelial control of blood flow in hypocholes-
teraemic rabbits have been described [29].
Apoptotic cell death is recognized to occur in
a number of vascular diseases, including atherosclero-
sis, restenosis, and hypertension [69]. Vascular endo-
thelial cells are continuously exposed to variations in
blood flow, which plays an important role in vessel
growth or regression and in the local development of
atherosclerosis. The shear stress that occurs during
changes in blood flow leads to a substantial release of
ATP (and UTP) from endothelial cells [24], and these
purines might mediate alterations in the balance be-
tween proliferation and apoptosis [60]. Occupation of
P2X￿ receptors leads to the production of proinflam-
matory cytokines [35] and tumor necrosis factor-
markedly increases endothelial cell apoptosis via the
activation of caspase 3 [69].
Restenosis
In restenosis following balloon angioplasty, there is
a peak in the proliferation and apoptosis of vascular
smooth muscle cells at ~14 days [49]. The first bal-
loon inflation during coronary angioplasty is a pre-
conditioning stimulus leading to a decrease in ische-
mia during later inflations; intracoronary adenosine
administration before coronary angioplasty modifies
the preconditioning effect of the first inflation [62].
Further studies show that adenosine preconditions hu-
16 ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿ ￿ ￿￿￿￿￿ ￿￿￿ ￿￿￿￿￿man myocardium against ischemia in vivo [64]. Ische-
mia and hypoxia lead to a substantial release of ATP
from endothelial cells [5] and ATP and adenosine are
released from hypoxic heart and skeletal muscle [13].
Diabetes
Along with its stimulating effect on bovine retinal
capillary endothelial cells, adenosine has been shown
to have an inhibitory effect on retinal pericytes, and it
has been hypothesized that this dual function plays
a role in the pathological neovascularisation process
that takes place in diabetes [56]. Diabetic microangio-
pathy has been implicated as a fundamental feature of
the pathological complications of diabetes, including
retinopathy, neuropathy, and foot ulceration [61].
Vascular pain
P2X￿ receptors are found on nociceptive sensory
nerve fibres and local release of ATP activates these
fibres sending messages to the pain centres in the
brain (see [20]). Burnstock speculated in 1996 [9] that
vascular pain, such as angina, migraine, ischemic
muscle pain, lumbar pain and pelvic pain, may in-
volve purinergic signalling. It was suggested that fol-
lowing local vasospasm, ATP released from
microvessel endothelial cells during the reactive hy-
peraemia that follows and is known to be associated
with pain, reaches P2X￿ receptors on the nociceptive
sensory fibres in the adventitia to initiate pain. This
concept was first proposed for the pain occurring in
migraine [17, 25]. In anginal pain, cardiac myocytes
as well as coronary microvessel endothelial cells may
be the source of ATP and adenosine reaching puriner-
gic nociceptors [32, 93].
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